A device for injecting an intraocular lens (IOL) into an eye, the device having an injector body including a lumen and an open tip wherethrough the IOL is expressed from the device. An IOL loading bay is located in the passageway wherein the IOL is positioned and compressed. The injector tip is dimensioned to allow the surgeon to choose an insertion depth between first, second and third transition points defined on the tip, the first and second transition points having a larger diameter than the third transition point which is located closer to the open tend of the tip. If the surgeon wishes to insert through a very small incision size (e.g., about 2.4 mm), the surgeon will insert the tip only up to the third transition point. The injector is stable during delivery of the IOL therethrough due to a spreading of the tip within the eye which effectively anchors the tip during IOL delivery.
|
1. An injector for delivering a foldable IOL into an eye, comprising:
an injector body having a tip comprising a first segment, a second segment and a third segment, the third segment extending to an open end of the injector body, the open end being adapted to permit the IOL to exit the injector into the eye,
at least one slot extending from the open end through the second segment and the third segment, the third segment connected to the second segment at a transition point, the transition point characterized by a change in taper of an outer dimension of the tip.
5. The injector of
6. The injector of
12. The injector of
14. The injector of
16. The injector of
17. The injector of
18. The injector of
|
The present invention relates to ophthalmic surgical devices and methods. More particularly, the present invention relates to a device and method for inserting an intraocular lens (IOL) into an eye.
IOLs are artificial lenses used to replace the natural crystalline lens of the eye when the natural lens has cataracts or is otherwise diseased. IOLs are also sometimes implanted into an eye to correct refractive errors of the eye in which case the natural lens may remain in the eye together with the implanted IOL. The IOL may be placed in either the posterior chamber or anterior chamber of the eye. IOLs come in a variety of configurations and materials. Some common IOL styles include the so-called open-looped haptics which include the three-piece type having an optic and two haptics attached to and extending from the optic; the one-piece type wherein the optic and haptics are integrally formed (e.g., by machining the optic and haptics together from a single block of material); and also the closed looped haptic IOLs. Yet a further style of IOL is called the plate haptic type wherein the haptics are configured as a flat plate extending from opposite sides of the optic. The IOL may be made from a variety of materials or combination of materials such as PMMA, silicone, hydrogels and silicone hydrogels, etc.
Various instruments and methods for implanting the IOL in the eye are known. In one method, the surgeon simply uses surgical forceps having opposing blades which are used to grasp the IOL and insert it through the incision into the eye. While this method is still practiced today, more and more surgeons are using more sophisticated IOL inserter devices which offer advantages such as affording the surgeon more control when inserting the IOL into the eye. IOL inserter devices have recently been developed with reduced diameter insertion tips which allow for a much smaller incision to be made in the cornea than is possible using forceps alone. Smaller incision sizes (e.g., less than about 3 mm) are preferred over larger incisions (e.g., about 3.2 to 5+mm) since smaller incisions have been attributed to reduced post-surgical healing time and complications such as induced astigmatism.
Since IOLs are very small and delicate articles of manufacture, great care must be taken in their handling. In order for the IOL to fit through the smaller incisions, they need to be folded and/or compressed prior to entering the eye wherein they will assume their original unfolded/uncompressed shape. The IOL inserter device must therefore be designed in such a way as to permit the easy passage of the IOL through the device and into the eye, yet at the same time not damage the delicate IOL in any way. Should the IOL be damaged during delivery into the eye, the surgeon will most likely need to extract the damaged IOL from the eye and replace it with a new IOL, a highly undesirable surgical outcome.
Thus, as explained above, the IOL inserter device must be designed to permit easy passage of the IOL therethrough. It is equally important that the IOL be expelled from the tip of the IOL inserter device and into the eye in a predictable orientation and manner. Should the IOL be expelled from the tip too quickly or in the wrong orientation, the surgeon must further manipulate the IOL in the eye which could result in trauma to the surrounding tissues of the eye. It is therefore highly desirable to have an inserter device which allows for precise loading of the IOL into the inserter device and which will pass and expel the IOL from the inserter device tip and into the eye in a controlled, predictable and repeatable manner.
To ensure controlled expression of the IOL through the tip of the IOL inserter device, the IOL must first be loaded into the IOL inserter device. The loading of the IOL into the inserter device is therefore a precise and very important step in the process. Incorrect loading of an IOL into the inserter device is oftentimes cited as the reason for a failed IOL delivery sequence. In a typical IOL inserter device, the IOL inserter utilizes a plunger having a tip which engages the IOL (which has been previously loaded and compressed into the inserter lumen) to pass it through the inserter lumen. The IOL thus interfaces with the plunger tip as well as the lumen of the inserter device. The lumen typically is dimensioned with a narrowing toward the open tip thereof in order to further compress the IOL as it is advanced through the lumen. The tip of the lumen is sized for insertion through the surgical incision which, as stated above, is presently preferred in the sub 3 mm range. Thus, an inserter lumen will typically be dimensioned larger at the load area of the IOL and gradually decrease in diameter to the tip of the lumen where the IOL is expressed into the eye. It will be appreciated that the compressed diameter of the IOL at the lumen tip is the same as the inner diameter of the lumen tip, preferably sub 3 mm as stated above. Each of these component interfaces are dynamic in the sense that the forces acting between the interfacing components (i.e., the IOL, the plunger tip and the inserter lumen) will vary as the IOL is pushed through the lumen. Control of these dynamic forces is therefore of utmost importance or otherwise the IOL may be damaged during delivery due to excessive compressive forces acting thereon. For example, as the IOL is advanced by the plunger through an ever-decreasing diameter lumen, the IOL is being compressed while at the same time the forces necessary to push the IOL through the lumen increase. This may lead to excessive force between the plunger tip and the IOL resulting in possible damage to the IOL and/or uncontrolled release of the IOL from the lumen tip. Also, the force of the plunger tip may cause the IOL to twist and/or turn as it is moved through the inserter whereby the force between the IOL and the plunger tip and/or the inserter lumen may uncontrollably increase to the point of IOL damage.
Various inserter devices have been proposed which attempt to address these problems, yet there remains a need for an IOL inserter and method which reliably places an IOL into an eye through a small incision and reduces the likelihood of IOL damage during delivery through the injector device.
The injector comprises a device body defining a longitudinal passageway (lumen) terminating at an open tip wherethrough the IOL is expressed from the injector into an eye. A plunger having a longitudinal plunger shaft and a plunger tip telescopes with the lumen of the device body. An opening is provided in the device body to access the lumen wherein an IOL is positioned. The injector includes means for compressing, rolling or otherwise forcing the IOL into a smaller cross-section for delivery through the injector. In one possible embodiment, the injector device includes a compressor drawer which extends laterally of the IOL loading bay of the injector body. The compressor drawer is movable between fully open and fully closed positions and is initially in the open position. Once the IOL is positioned in the opening or loading bay of the passageway, the compressor drawer is moved to the closed position which compresses the IOL. The plunger is advanced at the proximal end of the injector device causing the tip of the plunger to engage the proximal end of the compressed IOL. As the plunger is advanced further, the IOL is pushed through the open distal tip of the injector body and expressed into the eye in the intended manner.
For purposes of description, the tip may be considered as having four contiguous segments S1-S4 between the main body portion wherein the IOL is initially loaded into the device, and the open end of the tip. The first, proximal segment S1 is closest to the main body, the fourth, distal segment S4 includes the open tip, and the second and third segments S2, S3 extend sequentially therebetween. The first proximal segment S1 tapers gradually inwardly for a first length L1 to gradually further compress the IOL as it is being advanced by the plunger toward the open end of the tip. The second segment S2 preferably has a substantially constant diameter for a second length L2 which is preferably smaller than length L1. The juncture of the first and second lengths define a first transition point T1 having an outer diameter of about 2.7 mm to about 3.1 mm, and more preferably about 2.8 mm. Since the second segment S2 preferably remains constant in diameter, the IOL is not compressed any further as it is passed through this segment by the plunger and will not enlarge an incision of the same size. The third segment S3 tapers inwardly at a greater rate than the taper of segment S1 for a length L3 that is preferably smaller than L1 or L2. The juncture of the second and third segments S2, S3 define a second transition point T2 having an outer diameter the same as at T1. The fourth segment S4 preferably has a continuous cross-section extending for a length L4 also preferably smaller than L1 or L2, terminating in a slanted end face defining the open end of the tip. The juncture of the third and fourth segments S3, S4 defines a third transition point T3 that has an outer diameter in the range of about 2.0 to 2.6 mm and more preferably about 2.4 mm.
Some surgeons will use the injector device by inserting the tip up to the first or second transition points T1, T2 which have an outer diameter not exceeding about 3.0 mm. This means the incision in the eye need not be larger than about 3 mm. Current surgeon preference is to have an incision no larger than about 3 mm, and preferably sub 3 mm. Yet there are other surgeons that may prefer an even smaller incision size on the order of about 2.4 mm. For these surgeons, they may insert the tip up to only the third transition point T3 which, as stated above, has an outer diameter in the range of about 2.0 to 2.6 mm and more preferably about 2.4 mm.
At least one but preferably two slots extend from the second transition point T2 to the tip open end face. The slots reduce the hoop (radial) strength of the tip along the third and fourth segments for reasons explained below. The slots may colinearly extend from respective grooves extending along the inside wall of the lumen through the tip wherein opposite sides of the IOL optic slide during passage of the IOL through the device and into the eye. Since the slots reduce the hoop strength of the tip along segments S3 and S4, those segments can spread outwardly under the force exerted by the compressed IOL as it travels through those segments. For surgeons who prefer to insert the tip only up to the third transition point T3, the fourth segment S4 will spread open within the eye as the IOL is passed therethrough. This spreading action of this portion of the tip effectively “anchors” the inserted portion (segment S4) of the tip in the eye until the IOL has completely exited the device. This anchoring effect is important in preventing the surgeon from losing control of the IOL insertion process, especially in those circumstances where the surgeon prefers to insert only up to the point of the third transition point T3 to maintain a very small diameter incision (i.e., in the range of about 2.0 to 2.5 mm). To explain, with only a small length of the tip inserted through the incision (i.e., up to point T3), and without such anchoring of the tip within the eye, the force of the IOL exiting the tip may cause an inserter to decenter and/or kick back from the incision, possibly resulting in incorrect placement within the eye or the IOL expressing from the tip completely outside of the eye. The anchoring effect of the inventive tip thus ensures the tip will remain centered in the incision and in the eye until the IOL is completely expressed from the tip. Once the IOL is fully expressed from the tip into the eye, the resiliency of the tip causes the tip to return to its normal diameter allowing easy withdrawal from the eye with no stretching of the incision.
Referring to
Injector body 12 further includes an opening 26 which opens into lumen 14. Opening or “IOL loading bay” 26 accepts an IOL 30 therein for delivery of the IOL out distal tip 18a. In one possible embodiment, an IOL retainer 40 such as described in commonly owned copending application Ser. Nos. 10/651,785 and 10/813,862 incorporated herein by reference, is used for loading the IOL 30 into loading bay 26, it being understood other IOL loading methods may be employed (including simply placing IOL 30 in loading bay 26 with a pair of forceps, for example). As explained in more detail in these copending applications, the retainer 40 and IOL 30 may be coupled and packaged together or coupled to and packaged with an injector device 12 such that the surgeon or nurse need not handle and/or manipulate the IOL directly when loading the IOL 30 into the device 10. It is also understood that the IOL configuration shown and described herein is for discussion purposes only, and that the present invention is not to be limited thereby. The invention may be easily adapted to IOLs of any configuration and type (e.g., IOLs with plate, open or closed loop haptics, anterior chamber IOLs, posterior chamber IOLs, accommodating IOLs (including single and double lens types), etc.).
Referring still to
The injector includes means for compressing, rolling or otherwise forcing the IOL into a smaller cross-section for delivery through the injector. In the embodiment of
Prior to closing compressor drawer 60 and compressing the IOL 30 inside the injector body, it may be desirable to apply viscoelastic to the area surrounding the IOL 30 to ease delivery of the IOL through the injector body. This is a common practice in the industry and the amount and location of viscoelastic application varies according to the instructions for use provided with the device as well as the desires of the surgeon. Once the viscoelastic has been applied as desired, the compressor drawer 60 is moved to the fully closed position whereupon the IOL optic 31 is compressed and ready for delivery through a small incision formed in an eye. The surgeon inserts the injector tip 18a into the incision cut into the eye (reference numeral 13 in
For purposes of description, the injector tip may be considered as having four contiguous segments S1-S4 between the main body portion wherein the IOL is initially loaded into the device at an opening 26, and the open end of the tip 18a. It is understood that the tip may be separable from the main injector body or may be formed as a unitary construction therewith. The first, proximal segment S1 is closest to the main body 12, the fourth, distal segment S4 includes the open tip 18a, and the second and third segments S3, S3 extend sequentially therebetween. The first proximal segment S1 tapers gradually inwardly for a first length L1 (
At least one but preferably two slots 21a, 21b extend from the second transition point T2 to the tip open end face. The slots reduce the hoop (radial) strength of the tip along the third and fourth segments S3, S4 for reasons explained below. The slots may colinearly extend from respective grooves 14a, 14b (14b not shown but is coextensive with drawer groove 60a seen in
The injector tip is thus dimensioned to allow the surgeon to choose an insertion depth between first, second or third transition points defined on the tip, with the first and second transition points being larger in diameter than the third transition point and all diameters being about or less than 3 mm. If the surgeon wishes to insert through an incision around or just below 3 mm, the surgeon may insert the device up to the first or second transition point T1, T2. If the surgeon instead wishes to insert through a very small incision size (e.g., about 2.4 mm), the surgeon will insert the tip only up to the third transition point T3 and the insertion device will remain stable owing to the unique anchoring design thereof.
Heyman, Thomas M., Vaquero, Edward
Patent | Priority | Assignee | Title |
11083568, | Feb 07 2017 | RXSIGHT, INC | Intraocular lens inserter cartridge with an IOL-guiding structure |
Patent | Priority | Assignee | Title |
4573998, | Feb 05 1982 | GREYHOUND FINANCIAL CAPITAL CORPORATION | Methods for implantation of deformable intraocular lenses |
4681102, | Sep 11 1985 | MASTELLONE, CHARLES; BARTELL, MICHAEL | Apparatus and method for insertion of an intra-ocular lens |
4702244, | Feb 05 1982 | GREYHOUND FINANCIAL CAPITAL CORPORATION | Surgical device for implantation of a deformable intraocular lens |
4706669, | Jan 30 1984 | Device for perforating the lens capsule front wall in the eye of living beings | |
4715373, | Sep 27 1985 | Devices for implantation of deformable intraocular lens structures | |
4765329, | Oct 19 1987 | REDWITZ & WILSON, INC , 151 KALMUS DRIVE, SUITE F, #1, COSTA MESA, CALIFORNIA 92626, A CORP OF CA | Intraocular lens insertion instrument |
4834094, | Oct 07 1987 | Patton Medical Technologies, Inc.; PATTON MEDICAL TECHNOLOGIES, INC , | "Canoe" apparatus for inserting intra-ocular lens into the eye |
4836201, | Mar 24 1988 | Patton Medical Technologies, Inc.; PATTON MEDICAL TECHNOLOGIES, INC | "Envelope" apparatus for inserting intra-ocular lens into the eye |
4919130, | Nov 07 1986 | NESTLE S A | Tool for inserting compressible intraocular lenses into the eye and method |
4926877, | Apr 24 1989 | Biopsy needle with completely closable cutting end bore | |
4934363, | Dec 15 1987 | Iolab Corporation | Lens insertion instrument |
5123905, | Jun 07 1991 | KELMAN, ANN G | Intraocular lens injector |
5190552, | Feb 04 1992 | Slotted tube injector for an intraocular lens | |
5275604, | Dec 03 1992 | Abbott Medical Optics Inc | Contoured duct apparatus and method for insertion of flexible intraocular lens |
5304182, | Sep 23 1992 | Abbott Medical Optics Inc | Apparatus and method for curling and inserting flexible intraocular lenses |
5312413, | Jul 17 1991 | Instrumentation for ophthalmic surgery and method of using the same | |
5425734, | Jul 02 1993 | Abbott Medical Optics Inc | Intraocular lens injector |
5474562, | Mar 09 1993 | Chiron Vision Corporation | Apparatus and method for preparing an intraocular lens for insertion |
5494484, | Sep 30 1992 | STAAR Surgical Company | Deformable intraocular lens injecting device |
5496328, | Jul 15 1993 | STAAR JAPAN INC | Inserting device for deformable intraocular lens |
5499987, | Sep 30 1992 | STAAR Surgical Company | Deformable intraocular lens cartridge |
5772666, | Feb 15 1994 | STAAR SURGICAL COMPANY, INC | Deformable intraocular lens injecting apparatus with deformable tip plunger |
5810834, | Oct 07 1996 | Bausch & Lomb Incorporated | Tip formation for inserting a flexible membrane into an eye |
5876406, | Aug 02 1996 | STAAR SURGICAL COMPANY, INC | Deformable intraocular lens injecting apparatus with transverse hinged lens cartridge |
6010510, | Jun 02 1998 | Novartis AG | Plunger |
6056757, | Feb 14 1994 | STAAR SURGICAL COMPANY, INC | Implantation device with deformable nozzle tip for implanting a deformable intraocular lens |
6387101, | Oct 22 1999 | STAAR SURGICAL COMPANY, INC | Deformable intraocular lens injecting apparatus and method |
6447520, | Mar 19 2001 | JOHNSON & JOHNSON SURGICAL VISION, INC | IOL insertion apparatus with IOL engagement structure and method for using same |
6491697, | Sep 26 1996 | Bausch & Lomb Incorporated | Method and apparatus for inserting a flexible membrane into an eye |
20020022881, | |||
20020193805, | |||
20030216745, | |||
EP270257, | |||
JP5103808, | |||
WO164147, | |||
WO3077805, |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Mar 31 2004 | Bausch & Lomb Incorporated | (assignment on the face of the patent) | / | |||
Jun 29 2004 | VAQUERO, EDWARD | Bausch & Lomb Incorporated | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 014808 | /0251 | |
Jul 15 2004 | VAQUERO, EDWARD | Bausch & Lomb Incorporated | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 015073 | /0608 | |
Jul 15 2004 | HEYMAN, THOMAS M | Bausch & Lomb Incorporated | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 015073 | /0608 | |
Oct 26 2007 | BAUSCH & LOMB REALTY CORPORATION | CREDIT SUISSE | SECURITY AGREEMENT | 020122 | /0722 | |
Oct 26 2007 | BAUSCH & LOMB TECHNOLOGY CORPORATION | CREDIT SUISSE | SECURITY AGREEMENT | 020122 | /0722 | |
Oct 26 2007 | BAUSCH & LOMB INTERNATIONAL INC | CREDIT SUISSE | SECURITY AGREEMENT | 020122 | /0722 | |
Oct 26 2007 | BAUSCH & LOMB CHINA, INC | CREDIT SUISSE | SECURITY AGREEMENT | 020122 | /0722 | |
Oct 26 2007 | BAUSCH & LOMB SOUTH ASIA, INC | CREDIT SUISSE | SECURITY AGREEMENT | 020122 | /0722 | |
Oct 26 2007 | SIGHT SAVERS, INC | CREDIT SUISSE | SECURITY AGREEMENT | 020122 | /0722 | |
Oct 26 2007 | WILMINGTON MANAGEMENT CORP | CREDIT SUISSE | SECURITY AGREEMENT | 020122 | /0722 | |
Oct 26 2007 | WILMINGTON PARTNERS L P | CREDIT SUISSE | SECURITY AGREEMENT | 020122 | /0722 | |
Oct 26 2007 | B&L MINORITY DUTCH HOLDINGS LLC | CREDIT SUISSE | SECURITY AGREEMENT | 020122 | /0722 | |
Oct 26 2007 | Iolab Corporation | CREDIT SUISSE | SECURITY AGREEMENT | 020122 | /0722 | |
Oct 26 2007 | RHC HOLDINGS, INC | CREDIT SUISSE | SECURITY AGREEMENT | 020122 | /0722 | |
Oct 26 2007 | WP PRISM, INC | CREDIT SUISSE | SECURITY AGREEMENT | 020122 | /0722 | |
Oct 26 2007 | B&L VPLEX HOLDINGS, INC | CREDIT SUISSE | SECURITY AGREEMENT | 020122 | /0722 | |
Oct 26 2007 | B&L SPAF INC | CREDIT SUISSE | SECURITY AGREEMENT | 020122 | /0722 | |
Oct 26 2007 | B & L DOMESTIC HOLDINGS CORP | CREDIT SUISSE | SECURITY AGREEMENT | 020122 | /0722 | |
Oct 26 2007 | B&L CRL PARTNERS L P | CREDIT SUISSE | SECURITY AGREEMENT | 020122 | /0722 | |
Oct 26 2007 | B&L CRL INC | CREDIT SUISSE | SECURITY AGREEMENT | 020122 | /0722 | |
Oct 26 2007 | Bausch & Lomb Incorporated | CREDIT SUISSE | SECURITY AGREEMENT | 020122 | /0722 | |
Oct 26 2007 | B&L FINANCIAL HOLDINGS CORP | CREDIT SUISSE | SECURITY AGREEMENT | 020122 | /0722 | |
May 18 2012 | Credit Suisse AG, Cayman Islands Branch | Bausch & Lomb Incorporated | RELEASE BY SECURED PARTY SEE DOCUMENT FOR DETAILS | 028726 | /0142 | |
May 18 2012 | Bausch & Lomb Incorporated | CITIBANK N A , AS ADMINISTRATIVE AGENT | SECURITY AGREEMENT | 028728 | /0645 | |
May 18 2012 | EYEONICS, INC | CITIBANK N A , AS ADMINISTRATIVE AGENT | SECURITY AGREEMENT | 028728 | /0645 | |
Aug 05 2013 | CITIBANK N A , AS ADMINISTRATIVE AGENT | WP PRISM INC N K A BAUSCH & LOMB HOLDINGS INC | RELEASE OF SECURITY INTEREST | 030995 | /0444 | |
Aug 05 2013 | CITIBANK N A , AS ADMINISTRATIVE AGENT | Bausch & Lomb Incorporated | RELEASE OF SECURITY INTEREST | 030995 | /0444 | |
Aug 05 2013 | CITIBANK N A , AS ADMINISTRATIVE AGENT | ISTA PHARMACEUTICALS | RELEASE OF SECURITY INTEREST | 030995 | /0444 | |
Aug 30 2013 | Bausch & Lomb Incorporated | GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT | SECURITY AGREEMENT | 031156 | /0508 | |
Jan 08 2015 | GOLDMAN SACHS LENDING PARTNERS, LLC | BARCLAYS BANK PLC, AS SUCCESSOR AGENT | NOTICE OF SUCCESSION OF AGENCY | 034749 | /0689 | |
Jul 17 2017 | Bausch & Lomb Incorporated | The Bank of New York Mellon | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 043251 | /0932 | |
Feb 13 2018 | Valeant Pharmaceuticals International | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | VALEANT PHARMACEUTICALS NORTH AMERICA LLC | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | WIRRA IP PTY LIMITED | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | VALEANT PHARMA POLAND SP Z O O | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | VALEANT PHARMACEUTICALS LUXEMBOURG S A R L | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | VALEANT PHARMACEUTICALS IRELAND LIMITED | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | ORAPHARMA, INC | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | VALEANT CANADA LP | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | ATON PHARMA, INC | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | SYNERGETICS USA, INC | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | Technolas Perfect Vision GmbH | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | VALEANT CANADA LP | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | Valeant Pharmaceuticals International | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | VALEANT PHARMACEUTICALS NORTH AMERICA LLC | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | WIRRA IP PTY LIMITED | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | VALEANT PHARMA POLAND SP Z O O | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | VALEANT PHARMACEUTICALS LUXEMBOURG S A R L | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | VALEANT PHARMACEUTICALS IRELAND LIMITED | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | SOLTA MEDICAL, INC | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | SANTARUS, INC | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | Salix Pharmaceuticals, Ltd | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | Bausch & Lomb Incorporated | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | BAUSCH & LOMB PHARMA HOLDINGS CORP | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | COMMONWEALTH LABORATORIES, LLC | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | DOW PHARMACEUTICAL SCIENCES, INC | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | ECR PHARMACEUTICALS CO , INC | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | LABORATOIRE CHAUVIN S A S | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | Medicis Pharmaceutical Corporation | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | ONPHARMA INC | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | PRECISION DERMATOLOGY, INC | BARCLAYS BANK PLC, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0299 | |
Feb 13 2018 | ATON PHARMA, INC | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | Bausch & Lomb Incorporated | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | BAUSCH & LOMB PHARMA HOLDINGS CORP | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | SYNERGETICS USA, INC | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | SOLTA MEDICAL, INC | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | SANTARUS, INC | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | Salix Pharmaceuticals, Ltd | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | PRECISION DERMATOLOGY, INC | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | ORAPHARMA, INC | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | Technolas Perfect Vision GmbH | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | COMMONWEALTH LABORATORIES, LLC | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | DOW PHARMACEUTICAL SCIENCES, INC | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | ECR PHARMACEUTICALS CO , INC | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | LABORATOIRE CHAUVIN S A S | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | Medicis Pharmaceutical Corporation | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Feb 13 2018 | ONPHARMA INC | THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 045444 | /0634 | |
Mar 08 2019 | ORAPHARMA, INC | THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 048556 | /0758 | |
Mar 08 2019 | BAUSCH HEALTH AMERICAS, INC | THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 048556 | /0758 | |
Mar 08 2019 | Bausch & Lomb Incorporated | THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 048556 | /0758 | |
Mar 08 2019 | BAUSCH HEALTH US, LLC | THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 048556 | /0758 | |
Mar 08 2019 | SOLTA MEDICAL, INC | THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 048556 | /0758 | |
Mar 08 2019 | PRECISION DERMATOLOGY, INC | THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 048556 | /0758 | |
Mar 08 2019 | SALIX PHARMACEUTICALS, INC | THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 048556 | /0758 | |
Mar 08 2019 | SANTARUS, INC | THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 048556 | /0758 | |
Mar 08 2019 | Medicis Pharmaceutical Corporation | THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 048556 | /0758 | |
Jun 08 2021 | ORAPHARMA, INC | THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 056811 | /0814 | |
Jun 08 2021 | BAUSCH HEALTH AMERICAS, INC | THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 056811 | /0814 | |
Jun 08 2021 | PRECISION DERMATOLOGY, INC | THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 056811 | /0814 | |
Jun 08 2021 | SANTARUS, INC | THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 056811 | /0814 | |
Jun 08 2021 | SALIX PHARMACEUTICALS, INC | THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 056811 | /0814 | |
Jun 08 2021 | Medicis Pharmaceutical Corporation | THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 056811 | /0814 | |
Jun 08 2021 | SOLTA MEDICAL, INC | THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 056811 | /0814 | |
Jun 08 2021 | BAUSCH HEALTH US, LLC | THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 056811 | /0814 | |
Jun 08 2021 | Bausch & Lomb Incorporated | THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 056811 | /0814 | |
Feb 10 2022 | SANTARUS, INC | The Bank of New York Mellon | SECURITY AGREEMENT | 059121 | /0001 | |
Feb 10 2022 | ORAPHARMA, INC | The Bank of New York Mellon | SECURITY AGREEMENT | 059121 | /0001 | |
Feb 10 2022 | PRECISION DERMATOLOGY, INC | The Bank of New York Mellon | SECURITY AGREEMENT | 059121 | /0001 | |
Feb 10 2022 | BAUSCH HEALTH AMERICAS, INC | The Bank of New York Mellon | SECURITY AGREEMENT | 059121 | /0001 | |
Feb 10 2022 | SALIX PHARMACEUTICALS, INC | The Bank of New York Mellon | SECURITY AGREEMENT | 059121 | /0001 | |
Feb 10 2022 | Medicis Pharmaceutical Corporation | The Bank of New York Mellon | SECURITY AGREEMENT | 059121 | /0001 | |
Feb 10 2022 | SOLTA MEDICAL, INC | The Bank of New York Mellon | SECURITY AGREEMENT | 059121 | /0001 | |
Feb 10 2022 | BAUSCH HEALTH US, LLC | The Bank of New York Mellon | SECURITY AGREEMENT | 059121 | /0001 | |
Feb 10 2022 | Bausch & Lomb Incorporated | The Bank of New York Mellon | SECURITY AGREEMENT | 059121 | /0001 | |
May 10 2022 | Bausch & Lomb Incorporated | CITIBANK, N A AS COLLATERAL AGENT | PATENT SECURITY AGREEMENT | 059913 | /0548 | |
Oct 18 2022 | The Bank of New York Mellon | Technolas Perfect Vision GmbH | OMNIBUS PATENT SECURITY RELEASE AGREEMENT REEL FRAME 045444 0634 | 061872 | /0295 | |
Oct 18 2022 | The Bank of New York Mellon | LABORATOIRE CHAUVIN S A S | OMNIBUS PATENT SECURITY RELEASE AGREEMENT REEL FRAME 045444 0634 | 061872 | /0295 | |
Oct 18 2022 | The Bank of New York Mellon | The United States of America, as represented by the Secretary, Department of Health and Human Services | OMNIBUS PATENT SECURITY RELEASE AGREEMENT REEL FRAME 048556 0758 | 061872 | /0484 | |
Oct 18 2022 | The Bank of New York Mellon | Technolas Perfect Vision GmbH | OMNIBUS PATENT SECURITY RELEASE AGREEMENT REEL FRAME 048556 0758 | 061872 | /0484 | |
Oct 18 2022 | The Bank of New York Mellon | Bausch & Lomb Incorporated | OMNIBUS PATENT SECURITY RELEASE AGREEMENT REEL FRAME 045444 0634 | 061872 | /0295 | |
Oct 18 2022 | The Bank of New York Mellon | Technolas Perfect Vision GmbH | OMNIBUS PATENT SECURITY RELEASE AGREEMENT REEL FRAME 043251 0932 | 061872 | /0099 | |
Oct 18 2022 | The Bank of New York Mellon | Bausch & Lomb Incorporated | OMNIBUS PATENT SECURITY RELEASE AGREEMENT REEL FRAME 043251 0932 | 061872 | /0099 | |
Oct 18 2022 | The Bank of New York Mellon | Bausch & Lomb Incorporated | OMNIBUS PATENT SECURITY RELEASE AGREEMENT REEL FRAME 059121 0001 | 061873 | /0001 | |
Oct 18 2022 | The Bank of New York Mellon | BAUSCH HEALTH COMPANIES INC | OMNIBUS PATENT SECURITY RELEASE AGREEMENT REEL FRAME 048556 0758 | 061872 | /0484 | |
Oct 18 2022 | The Bank of New York Mellon | Bausch & Lomb Incorporated | OMNIBUS PATENT SECURITY RELEASE AGREEMENT REEL FRAME 056811 0814 | 061872 | /0669 | |
Oct 18 2022 | The Bank of New York Mellon | Bausch & Lomb Incorporated | OMNIBUS PATENT SECURITY RELEASE AGREEMENT REEL FRAME 048556 0758 | 061872 | /0484 | |
Oct 18 2022 | The Bank of New York Mellon | The United States of America, as represented by the Secretary, Department of Health and Human Services | OMNIBUS PATENT SECURITY RELEASE AGREEMENT REEL FRAME 045444 0634 | 061872 | /0295 | |
Oct 19 2022 | BARCLAYS BANK PLC | Bausch & Lomb Incorporated | RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS REEL FRAME 045444 0299 | 061779 | /0001 | |
Oct 19 2022 | BARCLAYS BANK PLC | Technolas Perfect Vision GmbH | RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS REEL FRAME 045444 0299 | 061779 | /0001 | |
Oct 19 2022 | BARCLAYS BANK PLC | The United States of America, as represented by the Secretary, Department of Health and Human Services | RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS REEL FRAME 045444 0299 | 061779 | /0001 | |
Oct 19 2022 | BARCLAYS BANK PLC | Bausch & Lomb Incorporated | RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS REEL FRAME 031156 0508 | 061778 | /0446 | |
Oct 19 2022 | BARCLAYS BANK PLC | LABORATOIRE CHAUVIN S A S | RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS REEL FRAME 045444 0299 | 061779 | /0001 | |
Oct 19 2022 | BARCLAYS BANK PLC | PF Consumer Healthcare 1 LLC | RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS REEL FRAME 045444 0299 | 061779 | /0001 | |
Oct 19 2022 | BARCLAYS BANK PLC | Bausch & Lomb Incorporated | RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS REEL FRAME 034749 0689 | 061778 | /0146 | |
Oct 19 2022 | BARCLAYS BANK PLC | University of Rochester | RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS REEL FRAME 034749 0689 | 061778 | /0146 | |
Sep 29 2023 | Bausch & Lomb Incorporated | CITIBANK, N A , AS NOTES COLLATERAL AGENT | PATENT SECURITY AGREEMENT | 065120 | /0086 |
Date | Maintenance Fee Events |
Feb 27 2017 | M1551: Payment of Maintenance Fee, 4th Year, Large Entity. |
Feb 24 2021 | M1552: Payment of Maintenance Fee, 8th Year, Large Entity. |
Date | Maintenance Schedule |
Sep 17 2016 | 4 years fee payment window open |
Mar 17 2017 | 6 months grace period start (w surcharge) |
Sep 17 2017 | patent expiry (for year 4) |
Sep 17 2019 | 2 years to revive unintentionally abandoned end. (for year 4) |
Sep 17 2020 | 8 years fee payment window open |
Mar 17 2021 | 6 months grace period start (w surcharge) |
Sep 17 2021 | patent expiry (for year 8) |
Sep 17 2023 | 2 years to revive unintentionally abandoned end. (for year 8) |
Sep 17 2024 | 12 years fee payment window open |
Mar 17 2025 | 6 months grace period start (w surcharge) |
Sep 17 2025 | patent expiry (for year 12) |
Sep 17 2027 | 2 years to revive unintentionally abandoned end. (for year 12) |